All In Biotech

Drug Trial Radar · NCT07429838

RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure

A Phase 1/2, First-in-Human Safety and Proof-of-Concept Study to Evaluate EGEN-5784 Porcine Liver (Drug Product) in Combination With the Metra® Extra-Corporeal Liver Cross-Circulation System in Participants With Acute-on-Chronic Liver Failure

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2027

Study completion Jan 2028

Sponsor

Lead sponsor
eGenesis, INCIndustry
Sponsor type
Industry
Collaborators
OrganOx Ltd.
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC system are designed to support liver function during the treatment period

Conditions

  • Acute on Chronic Liver Failure (ACLF)
  • Hepatic Encephalopathy (HE)

Interventions

  • metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx)Device

    Perfusion circuit/device enabling extracorporeal cross-circulation between the participant and the EGEN-5784 porcine liver. Planned support up to 72 h in Part 1 and up to 120 h in Part 2 if no safety/stopping criteria are met, with ICU-level monitoring and protocol-defined operating parameters.

  • EGEN-5784 (genetically engineered porcine liver)Biological

    Viable porcine liver from a genetically engineered donor (EGEN-5784) used for temporary extracorporeal cross-circulation support. The liver is not implanted; it is perfused in a closed circuit with the participant under continuous monitoring and predefined stopping rules per protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TESAE'sTime frame: From ELC initiation to 28 days post-ELC initiation
  2. Incidence of AESIsTime frame: From ELC initiation through 28 days post ELC initation
  3. Incidence of Device DeficienciesTime frame: From metra® initiation through metra® ELC termination (assessed continuously during the ELC procedure; up to 72 hours in Part 1 and 120 hours in Part 2)
  4. Incidence of UADEsTime frame: From metra® initiation through metra® ELC termination (assessed continuously during the ELC procedure; up to 72 hours in Part 1 and 120 hours in Part 2)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri

  • University of Wisconsin

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.